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Urinary cathecholamines, serum neurone specific enolase,
alpha-fetoprotein (AFP) and chorionic gonadotropin have a
diagnostic role as tumour markers in children with malignan-
cies. The new generation of tumour markers based on mono-
clonal antibodies has been extensively studied in adult
patients but little is known about their occurence in children.
The CA 125 antigen is based on monoclonal antibodies
originally raised against an ovarian serous cystadenocarcinoma
cell line and it associates in serum with mucin fraction (Bast et
al., 1983). Serum CA 125 is elevated in about 80% of patients
with ovarian cancer (Haglund, 1986), but it may also be
elevated in patients with other gynaecological or gastrointes-
tinal malignancies, and during pregnancy (Halila et al., 1986).
CA 19-9 is a tumour marker raised against a human
colorectal cell line (Koprowski et al., 1979). CA 19-9 is
immunohistochemically detectable in specimens from differ-
ent gastrointestinal cancers or from normal pancreas,
stomach, liver and gallbladder (Atkinson et al., 1982; Hag-
lund et al., 1986a). The serum concentrations are elevated
particularly in patients with pancreas cancer (Haglund et al.,
1986b; Herlyn et al., 1982), but also in patients with other
gastrointestinal cancer or some benign gastrointestinal
diseases (Herlyn et al., 1982).
Serum CA 19-9 and CA 125 measurements have not been
shown to be of clinical value in extra-abdominal tumours,
leukaemia or lymphoma of adult patients. This can be
expected, since these markers cannot be histochemically
located in the corresponding normal tissues.
Pregnancy-specific beta-l-glycoprotein (SPI) was originally
isolated from human placenta (Bohn, 1971), but closely
related antigens have subsequently been found in various
human cell lines (Rosen et al., 1979). SPI is also shown to be
a differentiation marker of the human myelomonocytic line-
age (Heikinheimo et al., 1987). These cells are capable of
synthesising SP1. Serum concentration of SP1 has not been
studied in disorders of the human haematopoietic system.
SPI is structurally homologous with carcinoembryonic anti-
gen (Rooney et al., 1988), another oncofetal antigen present
in serum samples from cancer patients. Thus far, the clinical
usefulness of SPI has been associated with patients with
trophoblast tumours (Rutanen et al., 1980).
This study was undertaken to evaluate the role of serum
concentrations of the two monoclonal tumour markers
CA 125, and CA 19-9, and the oncoplacental protein SPI in
children with leukaemia and other malignancies.
Our study group consisted of 127 children with leukaemias
or solid tumours, 51 girls and 76 boys, aged 0.2-16 years. Of
the patients, 37 had acute lymphoblastic leukaemia, five had
acute myeloid leukaemia, one had chronic myeloid leukae-
mia, 16 had lymphoma, ten had Wilm's tumour, 20 had
neuroblastoma, 16 had brain tumour, nine had bone tumour
and 13 had soft tissue sarcoma.
A serum sample was available from each patient at the
time of diagnosis and from 63 patients at 1 to 8 weeks
following diagnosis. In addition, serum samples from 52
healthy children, aged 1-17 years, collected for a nutritional
study (Kallio et al., 1989), were studied. Samples from 45
patients with acute infection without malignancy, and 12
children with active coeliac disease were available. The latter
two groups were included since infections and various benign
and malignant gastrointestinal diseases have been associated
with elevated serum concentrations of the tumour markers
(Herlyn et al., 1982).
Serum concentrations of CA 125, CA 19-9, SPI and AFP
were measured using radioimmunoassays (Halila et al., 1986;
Haglund et al., 1986a; Rutanen et al., 1980; Ruoslahti &
Seppiila, 1971). Statistical methods used were simple regres-
sion and correlation analyses and Student's t test.
The serum concentrations of CA 125, CA 19-9 and SPI
were similar in healthy individuals and in patients with acute
infection or coeliac disease (Table I). The range of serum
CA 19-9 levels in controls were clearly wider than in adults,
and the values in some healthy individuals were more than
100 U 1'. The analysis of the data showed that the age of
individuals did not have any influence on the concentrations
of the three markers. Further, the concentrations were also
mostly within the range of the reference group in patients
with leukaemia or solid tumours at diagnosis (Figure 1).
However, a few individuals with malignancies had serum
CA 125 and SPI values marginally exceeding the upper limit
of the reference values, as shown in Figure 1. The highest
CA 125 levels were seen in three children with a large
abdominal Burkitt's lymphoma causing partial intestinal ob-
struction in one of the patients. Involvement of the intestinal
wall could, however, not be verified in these cases.
Clearly elevated serum CA 125 was also found in two
children with acute T-cell leukaemia with intra-abdominal
organ and nodal involvement as well as in one patient with
stage II Wilm's tumour and in one patient with stage III
retroperitoneal neuroblastoma. There was no relationship in
general between any elevated marker levels and the extent of
disease in different diagnostic groups.
In 15 of the 34 patients with elevated CA 125 (n = 28)
and/or SPI (n = 8) at diagnosis, follow-up samples were
available at 1 to 6 weeks after diagnosis. In all these cases,
the values decreased to below the upper limit of the reference
values. On the other hand, follow-up samples were available
for 48 cases with initial concentrations within the reference
range. In ten of these patients the values were elevated above
the reference range, although the change was not significant.
All the patients, from which follow-up samples were avail-
able, received treatment for their disease. No difference in the
response to the therapy was noted between patients whose
marker level decreased, was stable or increased during the
follow-up period.
Serum concentrations of CA 19-9, CA 125 or SPI did not
correlate to those of serum alanine aminotranspherase, aspar-
tate aminotranspherase, creatinine, albumin, C-reactive pro-
tein or to the sedimentation rate. Neither did the marker
levels correlate to each other or to the serum AFP values.
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Table I Serum CA 19-9, CA 125 and SPI levels in healthy children and in patients with reactive
conditions
Healthy children Patients with
Infections Coeliac disease
n Median Range n Median Range n Median Range
CA 19-9 (Ul-') 52 11 <6.2-113 45 11 <6.2-71 12 8.8 <6.2-39
CA 125 (U1-') 52 12 <5.6-25 41 8 <5.6-68 12 14 <5.6-39
SPI (jIgl-') 17 <2.5 <2.5-5.7 45 <2.5 <2.5-4.3 0
0
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Figure 1 Serum CA 19-9, CA 125 and SPI concentrations in
healthy children and in patients with malignancies. In the lym-
phoma group the symbol (0) illustrates patients with Burkitt's
lymphoma. The light shaded area illustrates 90th percentile of
control subjects values, and the dark shaded area the detection
limit of the respective assay.
AFP levels were within the reference range in all 105 subjects
studied.
This is the first detailed study of the serum levels of
tumour markers CA 19-9, CA 125 and SPI in healthy chil-
dren and children with malignancies. The reference values for
the paediatric age group were established.
Serum CA 19-9, CA 125 and SPI concentrations are used
in the detection of germ cell tumours in children and in the
follow-up of these children (Heikinheimo et al., 1986), but
they are usually within normal limits in children with other
malignancies. In some cases, however, the levels of CA 125
and SPI are slightly elevated at diagnosis but normalise soon
after the induction of therapy. Although SPI has been shown
to be a marker for the human myelocyte-monocyte lineage,
children with acute myeloid leukaemia did not show elevated
serum levels of SPI. The number of these patients was,
however, low and further studies are needed to find out
whether SPI is released to the serum during the induction
phase of the treatment in these patients.
In this study, the highest CA 125 values were noted in
three patients with abdominal Burkitt's lymphoma. Unfor-
tunately follow-up samples were not available from these
patients. Our fourth patient with Burkitt's lymphoma,
localised to the tonsils, had a normal serum CA 125, and
elevation of this marker in three other patients may reflect
the gastrointestinal involvement of the disease, and be
unrelated to the type of the tumour. On the other hand,
markedly elevated CA 125 levels were occasionally seen in
other tumours, in which an abdominal involvement could not
always be demonstrated. More patients with Burkitt's lym-
phoma should, however, be studied and followed up, to see if
this tumour marker associates with tumour load and might
thus have clinical importance.
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